GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Forward PE Ratio

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Forward PE Ratio : 0.00 (As of Jun. 19, 2024)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Forward PE Ratio?

OncoVista Innovative Therapies's Forward PE Ratio for today is 0.00.

OncoVista Innovative Therapies's PE Ratio without NRI for today is 0.00.

OncoVista Innovative Therapies's PE Ratio for today is 0.00.


OncoVista Innovative Therapies Forward PE Ratio Historical Data

The historical data trend for OncoVista Innovative Therapies's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Forward PE Ratio Chart

OncoVista Innovative Therapies Annual Data
Trend
Forward PE Ratio

OncoVista Innovative Therapies Quarterly Data
Forward PE Ratio

Competitive Comparison of OncoVista Innovative Therapies's Forward PE Ratio

For the Biotechnology subindustry, OncoVista Innovative Therapies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Forward PE Ratio falls into.



OncoVista Innovative Therapies Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


OncoVista Innovative Therapies  (OTCPK:OVIT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


OncoVista Innovative Therapies Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines